Drug Profile
VRC EBOADC069 00 VP
Alternative Names: Bivalent Ebola adenoviral vector vaccine - NIAID/Okairos AG; Bivalent Ebola adenoviral vector vaccine - Okairos AG/NIAID; Bivalent Ebola vaccine - NIAID/Okairos AG; Bivalent Ebola vaccine - Okairos AG/NIAID; Bivalent Ebola virus vaccine - NIAID/Okairos AG; Bivalent Ebola virus vaccine - Okairos AG/NIAID; cAd3 EBO - NIAID/Okairos AG; cAd3-EBO - Okairos AG/NIAID; cAd3-EBO-S; chAd-EBOV - NIAID/Okairos AG; ChAd3-SUDV; Ebola sudan virus vaccine - Sabin; VRC-EBOADC069-00-VPLatest Information Update: 16 Jan 2023
Price :
$50
*
At a glance
- Originator National Institute of Allergy and Infectious Diseases; ReiThera
- Developer National Institute of Allergy and Infectious Diseases; Sabin Vaccine Institute; University of Maryland, Baltimore
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ebola virus infections
Most Recent Events
- 13 Jan 2023 VRC EBOADC069 00 V is still in phase-I development in Ebola-virus-infections (Prevention) in Mali, Uganda and USA (IM, Injection)
- 13 Jan 2023 Sabin Vaccine Institute receives grant under a development contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of VRC EBOADC069 00 VP and VRC MARADC087 00 VP
- 13 Jan 2023 Pooled efficacy data from preclinical and clinical trials in Ebola virus infections released by Sabin Vaccine Institute